table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID-19 mild to moderateCOVID-19 severe or critically
heparin at therapeutic dose RAPID ... REMAP-CAP Anticoagulation ATTACC ... ACTIV-4a ...

0 studies excluded by filtering options 1

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons